466 related articles for article (PubMed ID: 15772534)
1. Characterization of hepatocellular tumors: value of mangafodipir-enhanced magnetic resonance imaging.
Scharitzer M; Schima W; Schober E; Reimer P; Helmberger TK; Holzknecht N; Stadler A; Ba-Ssalamah A; Weber M; Wrba F
J Comput Assist Tomogr; 2005; 29(2):181-90. PubMed ID: 15772534
[TBL] [Abstract][Full Text] [Related]
2. Characterization of focal liver lesions: use of mangafodipir trisodium (MnDPDP)-enhanced MR images.
Karabacakoğlu A; Adigüzel Y; Karaköse S; Kayaçetin E; Haykir R
Turk J Gastroenterol; 2006 Sep; 17(3):164-71. PubMed ID: 16941248
[TBL] [Abstract][Full Text] [Related]
3. Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging.
Kim MJ; Kim JH; Lim JS; Oh YT; Chung JJ; Choi JS; Lee WJ; Kim KW
J Magn Reson Imaging; 2004 Oct; 20(4):612-21. PubMed ID: 15390224
[TBL] [Abstract][Full Text] [Related]
4. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
Wang C
Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
[TBL] [Abstract][Full Text] [Related]
5. Benign and malignant hepatocellular tumors: evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging.
Coffin CM; Diche T; Mahfouz A; Alexandre M; Caseiro-Alves F; Rahmouni A; Vasile N; Mathieu D
Eur Radiol; 1999; 9(3):444-9. PubMed ID: 10087113
[TBL] [Abstract][Full Text] [Related]
6. Contrast-enhanced MRI of the liver with mangafodipir trisodium: imaging technique and results.
Sahani DV; O'Malley ME; Bhat S; Hahn PF; Saini S
J Comput Assist Tomogr; 2002; 26(2):216-22. PubMed ID: 11884777
[TBL] [Abstract][Full Text] [Related]
7. Assessment of sequential enhancement patterns of focal nodular hyperplasia and hepatocellular carcinoma on mangafodipir trisodium enhanced MR imaging.
Savellano DH; Köstler H; Baus S; Mössinger M; Gratz KF; Weimann A; Galanski M
Invest Radiol; 2004 May; 39(5):305-12. PubMed ID: 15087726
[TBL] [Abstract][Full Text] [Related]
8. [Use of SPIO-enhanced T1- and T2-weighted images for the differentiation of liver lesions: an ROC analysis].
Stroszczynski C; Gaffke G; Gretschel S; Rambow A; Jost D; Schlecht I; Schneider U; Schicke B; Hohenberger P; Gebauer B; Felix R
Rofo; 2003 Oct; 175(10):1368-75. PubMed ID: 14556106
[TBL] [Abstract][Full Text] [Related]
9. Mangafodipir trisodium-enhanced MRI for the detection and characterization of focal hepatic lesions: is delayed imaging useful?
Chung JJ; Kim MJ; Kim KW
J Magn Reson Imaging; 2006 May; 23(5):706-11. PubMed ID: 16565954
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP).
Murakami T; Baron RL; Peterson MS; Oliver JH; Davis PL; Confer SR; Federle MP
Radiology; 1996 Jul; 200(1):69-77. PubMed ID: 8657947
[TBL] [Abstract][Full Text] [Related]
11. T2-weighted MR imaging in the assessment of cirrhotic liver.
Hussain HK; Syed I; Nghiem HV; Johnson TD; Carlos RC; Weadock WJ; Francis IR
Radiology; 2004 Mar; 230(3):637-44. PubMed ID: 14739306
[TBL] [Abstract][Full Text] [Related]
12. MR imaging features for improved diagnosis of hepatocellular carcinoma in the non-cirrhotic liver: Multi-center evaluation.
Fischer MA; Raptis DA; Donati OF; Hunziker R; Schade E; Sotiropoulos GC; McCall J; Bartlett A; Bachellier P; Frilling A; Breitenstein S; Clavien PA; Alkadhi H; Patak MA
Eur J Radiol; 2015 Oct; 84(10):1879-87. PubMed ID: 26194029
[TBL] [Abstract][Full Text] [Related]
13. Mn-DPDP enhancement patterns of hepatocellular lesions on MR images.
Vogl TJ; Hamm B; Schnell B; McMahon C; Branding G; Lissner J; Wolf KJ
J Magn Reson Imaging; 1993; 3(1):51-8. PubMed ID: 8381314
[TBL] [Abstract][Full Text] [Related]
14. Preoperative detection of hepatocellular carcinoma: ferumoxides-enhanced versus mangafodipir trisodium-enhanced MR imaging.
Kim SK; Kim SH; Lee WJ; Kim H; Seo JW; Choi D; Lim HK; Lee SJ; Lim JH
AJR Am J Roentgenol; 2002 Sep; 179(3):741-50. PubMed ID: 12185056
[TBL] [Abstract][Full Text] [Related]
15. Defining intrahepatic biliary anatomy in living liver transplant donor candidates at mangafodipir trisodium-enhanced MR cholangiography versus conventional T2-weighted MR cholangiography.
Lee VS; Krinsky GA; Nazzaro CA; Chang JS; Babb JS; Lin JC; Morgan GR; Teperman LW
Radiology; 2004 Dec; 233(3):659-66. PubMed ID: 15516606
[TBL] [Abstract][Full Text] [Related]
16. MRI for detection of hepatocellular carcinoma: comparison of mangafodipir trisodium and gadopentetate dimeglumine contrast agents.
Youk JH; Lee JM; Kim CS
AJR Am J Roentgenol; 2004 Oct; 183(4):1049-54. PubMed ID: 15385303
[TBL] [Abstract][Full Text] [Related]
17. Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents.
Ba-Ssalamah A; Schima W; Schmook MT; Linnau KF; Schibany N; Helbich T; Reimer P; Laengle F; Wrba F; Kurtaran A; Ryan M; Mann FA
AJR Am J Roentgenol; 2002 Dec; 179(6):1447-56. PubMed ID: 12438034
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
[TBL] [Abstract][Full Text] [Related]
19. Uptake of mangafodipir trisodium (MnDPDP) by hepatocellular carcinoma: correlation with unenhanced imaging findings and histopathologic features.
Chezmar JL; Redvanly RD; Sewell CW
Acad Radiol; 1996 Aug; 3 Suppl 2():S413-4. PubMed ID: 8796617
[No Abstract] [Full Text] [Related]
20. Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging.
Quaia E; Pizzolato R; De Paoli L; Angileri R; Ukmar M; Cova MA
J Magn Reson Imaging; 2013 Apr; 37(4):892-902. PubMed ID: 23097278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
